Northwest Biotherapeutics change, expands management team
Northwest Biotherapeutics (NWBT), a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments and without toxicities, has added several executives to its management team.
Linda Powers, Chairman of the Board since May 2007, has been appointed Chief Executive Officer. Dr. Anthony Maida, an executive in the field of cancer immune therapies, joins as Chief Operating Officer. Dr. Alton Boynton, the scientific founder of NWBT and has served as CEO since May 2007, is returning to his position as Chief Scientific Officer. Les Goldman, a former longtime partner at Skadden, Arps specializing in advanced technology commercialization, has been appointed Senior Vice President, Business Development.
Dr. Maida brings more than 20 years of experience in building oncology companies, with expertise in the business and financial aspects, the clinical and regulatory aspects and the underlying science. He has held positions as Chairman, CEO, COO, CSO, CFO and VP Business Development, and has raised nearly $200 million in financings. He served as CEO of CancerVax, an early leader in cancer vaccines, raising the company's first $30 million of funding. Dr. Maida also served as global head of Oncology for a CRO. He recently completed and in 2010 received a Ph.D. in Tumor Immunology.
Goldman was a partner at law firm Skadden, Arps for over 30 years, specializing in a wide array of advanced technologies and their commercialization. He also serves as an advisor to a number of other technology companies.